Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

168.02 -1.39 (-0.82%)
Streaming Delayed Price Updated: 10:39 AM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
3 Small-Cap Stocks That Fall Short
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Topics Electric Vehicles
News headline image
Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ)
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Mid-Cap Stocks with Warning Signs
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
3 Reasons JAZZ is Risky and 1 Stock to Buy Instead
The past six months have been a windfall for Jazz Pharmaceuticals’s shareholders. The company’s stock price has jumped 50.6%, hitting $163 per share. This was partly due to its solid quarterly results,... 
Via StockStory
Topics Bankruptcy
News headline image
3 Value Stocks We’re Skeptical Of
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters. 
Via The Motley Fool
News headline image
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗
Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down. 
Via The Motley Fool
News headline image
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Healthcare Stocks We’re Skeptical Of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand,... 
Via StockStory
Topics Stocks
News headline image
Stocks making big moves yesterday: Dycom, ACV Auctions, Jazz Pharmaceuticals, Coinbase, and Gibraltar
Check out the companies making headlines yesterday: 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks Walking a Fine Line
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer ↗
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares are popping on Monday following the company's positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with... 
Via Benzinga
News headline image
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions. 
Via Benzinga
News headline image
Why Is Jazz Pharmaceuticals (JAZZ) Stock Soaring Today
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 18.3% in the morning session after the company announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for its... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Monday's session. ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Mixed Signals Point to Cautious Open for U.S. Markets as Tech Shines Amidst Economic Data Delays
U.S. equity futures are signaling a mixed but largely cautious start to the trading day on November 17, 2025, with technology stocks once again taking the lead, while broader indices like the Dow Jones... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗
Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
The Top 5 Analyst Questions From Jazz Pharmaceuticals’s Q3 Earnings Call
Jazz Pharmaceuticals delivered a quarter that exceeded Wall Street’s expectations, with management attributing results to robust demand for Xywav and Epidiolex, as well as the swift and successful... 
Via StockStory
Topics Earnings
News headline image
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
JAZZ Q3 Deep Dive: New Drug Launches and Portfolio Expansion Drive Strong Results
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 6.7% year on year to $1.13 billion. The company expects the... 
Via StockStory
News headline image
Jazz Pharma (JAZZ) Earnings Call Transcript ↗
Jazz Pharma (JAZZ) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Jazz Pharmaceuticals’s (NASDAQ:JAZZ) Q3: Beats On Revenue
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 6.7% year on year to $1.13 billion. The company expects the full... 
Via StockStory
Topics Supply Chain
News headline image
Insights into Jazz Pharmaceuticals's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q3 Results Tomorrow
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings this Wednesday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Unprofitable Stock with Promising Prospects and 2 Facing Headwinds
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
Jazz Pharmaceuticals trades at $138.50 and has moved in lockstep with the market. Its shares have returned 27.1% over the last six months while the S&P 500 has gained 22.9%. 
Via StockStory
Topics Government Stocks World Trade
News headline image
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz ↗
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.